GET THE APP
Paget Disease Innovations | Open Access Journals
Journal of Bioanalysis & Biomedicine

Journal of Bioanalysis & Biomedicine

ISSN: 1948-593X

Open Access
Spanish Chinese Russian German French Japanese Portuguese Hindi Telugu Tamil
Submit Manuscript arrow_forward arrow_forward ..

Paget Disease Innovations

Paget's disease of the bone was first described by the English surgeon, Sir James Paget, in 1876. The prevalence varies worldwide but is particularly high in the United Kingdom. The affected bones change in size and shape and the disease can cause considerable morbidity. Until relatively recently, there was no effective treatment. Over the past five years, however, the availability of potent anti-resorption drugs has transformed the outlook for patients with the disease.

This article reviews the epidemiology, clinical features and management of the disease and examines how early recognition and treatment can help reduce the morbidity associated with it.

Several bisphosphonates are currently authorized for use in Paget's disease in the United Kingdom. Bisphosphonates inhibit osteoclastic activity, thereby reducing bone resorption. Oral etidronate was the first bisphosphonate to be approved and was associated with an approximately 50% reduction in disease activity (measured using alkaline phosphatase). One limitation of etidronate was that, at the therapeutic doses necessary to reduce disease activity, some patients had side effects, including impaired bone mineralization.

In the past five years, new, more potent bisphosphonates that are much more effective in reducing disease activity have been licensed in the UK. These include tiludronate, risedronate and intravenous pamidronate. Tiludronate is administered orally at a dose of 400 mg daily for a period of three months. Risedronate is taken by mouth at a dose of 30 mg daily for a period of two months. These two treatments are associated with an approximately 80% reduction in disease activity (Roux et al, 1995; Hosking et al, 1998). Oral bisphosphonates are poorly absorbed and should be taken on an empty stomach, with food being delayed after taking the medication. They should be taken with water in an upright position.

High Impact List of Articles
Conference Proceedings

Relevant Topics in Pharmaceutical Sciences

Awards & Nominations

50+ Million Readerbase

Journal Highlights

Google Scholar citation report
Citations: 3099

Journal of Bioanalysis & Biomedicine received 3099 citations as per Google Scholar report

Citation image
Journal of Bioanalysis & Biomedicine peer review process verified at publons
Publon image

Indexed In

Related Links

PMC/PubMed Indexed Articles
Hepatic Endosome Protein Profiling in Apolipoprotein E Deficient Mice Expressing Apolipoprotein B48 but not B100
 

Open Access Journals

arrow_upward arrow_upward
https://www.olimpbase.org/1937/